Published on 8 May 2024 on Simply Wall St. via Yahoo Finance
When Can We Expect A Profit From Coherus BioSciences, Inc. (NASDAQ:CHRS)?
With the business potentially at an important milestone, we thought we'd take a closer look at Coherus BioSciences, Inc.'s (NASDAQ:CHRS) future prospects. Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. On 31 December 2023, the US$255m market-cap company posted a loss of US$238m for its most recent financial year. Many investors are wondering about the rate at which Coherus BioSciences will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company.
Check out our latest analysis for Coherus BioSciences